zika
viru
zikv
mosquitoborn
flaviviru
almost
neglect
pathogen
introduct
america
respons
threat
global
health
caus
great
social
sanitari
alarm
due
increas
virul
rapid
spread
associ
sever
neurolog
ophthalmolog
complic
current
specif
antivir
therapi
zikv
avail
treatment
palli
mainli
direct
toward
relief
symptom
fever
rash
administ
antipyret
antihistamin
fluid
dehydr
nevertheless
late
search
antivir
major
aim
zikv
investig
screen
librari
differ
sourc
test
natur
compound
repurpos
drug
known
antivir
activ
allow
identif
sever
antivir
candid
direct
viral
structur
protein
enzym
cellular
element
present
updat
review
current
knowledg
antizikv
strategi
focus
hostdirect
antivir
realist
altern
combat
zikv
infect
sinc
begin
centuri
number
infecti
diseas
threat
emerg
demand
global
respons
among
sever
acut
respiratori
syndrom
viru
avian
influenza
human
pandem
influenza
middl
east
respiratori
syndrom
coronaviru
chikungunya
viru
ebola
viru
threaten
one
nonetheless
emerg
vectorborn
viru
zika
viru
zikv
respons
congenit
malform
neurolog
ophthalmolog
disord
hard
predict
zikv
mosquitoborn
viru
belong
spondweni
serocomplex
genu
flaviviru
famili
flavivirida
viru
isol
variou
mosquito
speci
although
seem
natur
transmiss
vector
mosquito
genu
aed
besid
mosquito
bite
viral
direct
humantohuman
transmiss
occur
perinat
sexual
breastfeed
blood
transfus
zikv
genom
singlestrand
rna
molecul
kb
posit
polar
encod
singl
open
read
frame
orf
flank
two
untransl
region
end
zikv
first
isol
serum
monkey
one
year
later
aed
africanu
mosquito
caught
area
zika
forest
detect
asia
viru
confin
africa
later
human
outbreak
report
pacif
island
micronesia
french
polynesia
natur
cours
zikv
infect
usual
asymptomat
produc
rel
mild
ill
unev
recoveri
henc
viru
consid
almost
neglect
pathogen
recent
introduct
america
becam
threat
global
health
show
increas
virul
rapid
spread
sinc
recent
outbreak
america
quit
high
number
possibl
antivir
candid
test
vitro
vivo
howev
specif
therapi
approv
flaviviru
includ
zikv
thu
current
treatment
mainli
direct
toward
relief
symptom
fever
rash
administ
antipyret
antihistamin
fluid
dehydr
nevertheless
note
commonli
use
drug
acetylsalicyl
acid
contraind
zikvinfect
patient
sinc
increas
risk
intern
bleed
arbovirus
dengu
chikungunya
virus
coinfect
patient
may
produc
hemorrhag
due
natur
cours
zikv
infect
usual
asymptomat
produc
rel
mild
ill
unev
recoveri
face
antizikv
strategi
import
point
take
account
main
target
popul
would
benefit
name
immunocompromis
patient
pregnant
women
fetus
sens
test
drug
safeti
profil
known
howev
case
food
drug
administr
fda
http
wwwdrugscom
categori
b
compound
anim
reproduct
studi
fail
demonstr
risk
fetu
adequ
wellcontrol
studi
pregnant
women
even
categori
c
anim
reproduct
studi
shown
advers
effect
fetu
adequ
wellcontrol
studi
human
potenti
benefit
may
warrant
use
drug
pregnant
women
despit
potenti
risk
posit
evid
human
fetal
risk
base
advers
reaction
data
investig
market
experi
studi
human
potenti
benefit
may
warrant
use
drug
pregnant
women
despit
potenti
risk
use
pregnanc
contempl
potenti
benefit
outweigh
risk
even
assay
compound
cross
placenta
thu
also
benefit
fetu
nonetheless
use
done
individu
way
condit
dosag
time
alway
clinician
control
patient
inform
pro
con
current
search
zikv
antivir
conduct
differ
approach
screen
compound
librari
repurpos
drug
known
activ
efficaci
diseas
use
clinic
practic
mani
display
broadspectrum
activ
test
natur
product
two
differ
strategi
appli
pursu
antivir
search
compound
direct
viral
target
directact
antivir
aim
target
cellular
compon
need
viral
life
cycl
hostdirect
antivir
among
virusdirect
drug
test
act
viral
rnadepend
rna
polymeras
nonstructur
protein
catalyt
domain
includ
nucleosid
analog
polymeras
inhibitor
methyltransferas
catalyt
domain
respons
transfer
mrna
cap
trypsinlik
serin
proteas
need
proper
process
viral
polyprotein
helicas
crystal
structur
protein
alreadi
resolv
certainli
help
find
new
antivir
way
structur
viral
protein
also
avail
could
help
design
zikv
therapeut
altern
capsid
c
protein
whose
destabil
may
impair
zikv
multipl
immunomodul
envelop
glycoprotein
mediat
cell
bind
endosom
fusion
constitut
major
target
neutral
antibodi
could
also
target
virucid
compound
hand
also
report
passiv
transfer
neutral
antibodi
pregnant
mice
suppress
zikv
multipl
inhibit
cell
death
reduc
number
progenitor
neuron
cell
prevent
microcephali
likewis
administr
monoclon
antibodi
mab
recogn
domain
iii
zikv
protein
protect
mice
lethal
zikv
challeng
mab
abl
bind
neutral
zikv
includ
direct
e
dimer
epitop
human
polyclon
antibodi
produc
transchromosom
bovin
also
protect
mice
zikv
lethal
infect
elimin
zikv
induc
tissu
damag
brain
test
protect
testicular
atrophi
thu
administr
therapeut
antibodi
seem
also
potenti
strategi
zikv
nevertheless
note
although
still
controverti
case
zikv
infect
wellknown
antibodi
depend
enhanc
effect
ade
dengu
viru
denv
prototyp
model
may
potenti
risk
diseas
exacerb
flavivirus
small
rna
genom
around
kb
length
thu
requir
mani
host
factor
cooption
cellular
metabol
pathway
success
infect
host
cell
propag
effici
offer
opportun
search
host
target
therapeut
tool
mani
instanc
share
differ
member
flavivirida
famili
envisag
panflavivir
antivir
strategi
direct
host
factor
implic
infect
pathogenesi
immun
respons
shown
denv
west
nile
viru
wnv
addit
effect
would
less
prone
emerg
mutant
escap
action
often
occur
drug
target
viral
compon
consequ
kind
approach
could
ideal
lead
discoveri
broad
spectrum
antivir
could
provid
low
cost
effect
tool
control
flavivir
threat
differ
approach
use
identifi
potenti
host
factor
therapeut
target
flavivirus
includ
analys
transcript
level
eg
next
gener
rna
sequenc
alter
express
pattern
infect
proteom
chang
kinas
activ
variat
proteinrna
interact
eg
twohybrid
screen
affin
chromatographi
likewis
function
analysi
appli
overexpress
cdna
rnaimedi
loss
function
screen
use
dsrna
sirna
shrna
librari
although
note
case
downregul
ineffici
gene
redund
function
replicon
may
also
use
specif
assay
replic
activ
theoret
hostact
antivir
direct
molecul
pathway
implic
differ
step
viral
life
cycl
earli
event
bind
entri
fusion
format
replic
complex
viral
matur
egress
first
step
zikv
infect
bind
cellular
receptor
figur
sever
molecul
propos
zikv
receptor
member
tam
famili
receptor
tyrosin
kinas
tcell
immunoglobulin
mucin
domain
tim
dendrit
cellspecif
intercellular
adhes
molecul
nonintegrin
dcsign
express
differ
neuron
nonneuron
permiss
cell
type
molecul
also
receptor
virus
includ
flavivirus
denv
wnv
regul
sever
cellular
activ
adhes
migrat
prolifer
surviv
releas
inflammatori
cytokin
antigen
uptak
signal
play
import
role
host
respons
infect
howev
elimin
known
receptor
necessarili
result
complet
protect
viral
infect
sinc
flavivirus
use
differ
receptor
thu
alway
redund
altern
instanc
inhibit
downregul
knockingdown
ablat
axl
although
case
reduc
zikv
infect
complet
abolish
point
use
differ
cell
surfac
receptor
differ
cell
type
differ
molecul
shown
inhibit
zikv
infect
entri
step
figur
axl
kinas
inhibitor
axl
decoy
receptor
compromis
complet
abolish
zikv
infect
glial
cell
well
cabozantinib
inhibitor
axl
phosphoryl
current
clinic
trial
anticanc
activ
significantli
impair
zikv
infect
human
endotheli
cell
dosedepend
manner
affect
postbind
step
likewis
curcumin
wide
use
food
addit
herbal
supplement
reduc
zikv
infect
cell
cultur
inhibit
cell
bind
maintain
viral
rna
integr
suramin
antiparasit
interfer
attach
host
cell
virion
biogenesi
affect
glycosyl
matur
zikv
bind
cell
receptor
like
flavivirus
intern
clathrinmedi
endocytosi
transport
endosom
involv
cellular
actin
microtubul
establish
product
infect
figur
intern
start
translat
replic
viral
genom
releas
insid
cytoplasm
fuse
viral
envelop
membran
cellular
endosom
process
trigger
acid
ph
insid
nanchangmycin
insecticid
antibacteri
polyeth
inhibit
zikv
multipl
although
exact
mechan
action
complet
elucid
probabl
target
axl
block
clathrinmedi
endocytosi
acid
endosom
ph
trigger
rapid
conform
chang
viral
envelop
protein
result
fusion
endosom
membran
phdepend
manner
thu
allow
nucleocapsid
releas
cytoplasm
genom
uncoat
figur
optim
ph
conform
rearrang
viral
fusion
process
like
depend
presenc
cholesterol
specif
lipid
target
membran
process
potenti
druggabl
fact
arbidol
broadspectrum
antivir
immunomodulatori
use
human
influenza
b
infect
inhibit
zikv
multipl
cell
cultur
probabl
intercal
membran
lipid
lead
inhibit
membran
fusion
viru
particl
plasma
membran
viru
particl
membran
endosom
chlorpromazin
antipsychot
drug
also
inhibit
clathrinmedi
endocytosi
reduc
zikv
infect
confirm
requir
clathrinmedi
endocytosi
zikv
addit
increas
zikvinfect
human
embryon
cell
brain
organoid
reduc
viremia
viral
load
without
affect
viral
bind
block
intern
suppress
viral
cell
membran
fusion
even
reduc
mortal
prevent
microcephali
zikvinfect
mice
also
decreas
viral
load
urin
serum
treat
nonhuman
infect
primat
daptomycin
lipopeptid
antibiot
insert
cell
membran
rich
phosphatidylglycerol
suggest
effect
late
endosom
membran
enrich
lipid
also
describ
zikv
inhibitor
depend
endosom
acidif
zikv
infect
also
provid
host
target
suitabl
antivir
intervent
instanc
obatoclax
antineoplast
proapoptot
inhibitor
target
cellular
impair
zikv
endocyt
uptak
reduc
ph
endosom
vesicl
cell
cultur
therebi
like
inhibit
viral
fusion
howev
obatoclax
present
low
solubl
produc
satisfactori
result
clinic
trial
hematolog
myeloid
diseas
saliphenylhalamid
saliph
target
vacuolar
adenosin
triphosphatas
enzym
atpas
block
acidif
endosom
inhibit
zikv
multipl
human
retin
pigment
epitheli
cell
natur
target
zikv
infect
similar
result
found
adcock
et
al
saliph
use
differ
screen
howev
report
contrari
describ
other
compound
interfer
endocyt
pathway
dynasor
block
clathrinmedi
endocytosi
monensin
cation
transport
either
toxic
cell
use
show
antizikv
activ
neither
chloroquin
cq
contradictori
result
probabl
explain
differ
methodolog
cell
type
lower
extent
viral
strain
use
analyz
antivir
activ
compound
suggest
compound
show
differ
activ
care
evalu
go
investig
line
contrari
mention
report
cq
fdaapprov
antiinflammatori
autophagi
inhibitor
wide
use
antimalaria
drug
administ
pregnant
women
risk
exposur
plasmodium
parasit
shown
antizikv
activ
differ
cell
type
vero
cell
human
brain
microvascular
endotheli
cell
hbmec
human
neural
stem
cell
nsc
affect
earli
stage
viral
life
cycl
possibl
rais
endosom
ph
inhibit
fusion
envelop
protein
endosom
membran
cq
shown
reduc
placent
fetal
zikv
infect
also
attenu
zikvassoci
morbid
mortal
mice
protect
fetu
microcephali
even
cq
attenu
vertic
transmiss
zikvinfect
pregnant
interferon
signalingcompet
swiss
jim
lambert
sjl
mice
significantli
reduc
fetal
brain
viral
load
similarli
cq
lysosomotrop
agent
ammonium
chlorid
bafilomycin
quinacrin
mefloquin
ntertbutyl
isoquin
neutral
acid
ph
endosom
compart
block
infect
human
fibroblast
cell
line
vero
cell
addit
medicin
chemistrydriven
approach
seri
new
trifluoromethyl
quinolin
n
arylmethylimino
ethyl
deriv
prove
inhibit
zikv
replic
vitro
higher
potenc
chloroquin
mefloquin
recent
screen
fdaapprov
drug
use
cellbas
assay
shown
amodiaquin
anoth
antimalari
drug
also
antizikv
activ
cell
cultur
target
earli
event
viral
replic
cycl
niclosamid
categori
b
antihelmint
drug
approv
fda
capabl
inhibit
zikv
infect
although
antiflavivir
effect
associ
abil
neutral
endolysosom
ph
interfer
phdepend
membran
fusion
case
zikv
seem
affect
postentri
step
addit
recent
report
niclosamid
decreas
zikv
product
partial
restor
differenti
prevent
apoptosi
human
induc
nsc
even
partial
rescu
zikvinduc
microcephali
attenu
infect
develop
human
zikvinfect
embryo
model
vivo
likewis
repress
cell
growth
induc
apoptosi
cell
express
inhibit
proteindeacetyl
activ
thu
affect
endosom
function
potent
inhibit
zikv
infect
primari
placent
fibroblast
cell
iron
salt
ferric
ammonium
citrat
fac
also
inhibit
zikv
infect
induc
viral
fusion
block
endosom
viral
releas
promot
liposom
aggreg
intracellular
vesicl
fusion
overal
studi
evid
potenti
target
viral
entri
combat
zikv
zikvrna
releas
endosom
cytoplasm
act
mrna
synthes
negativestrand
viral
rna
direct
positivestrand
rna
synthesi
figur
silvestrol
natur
compound
isol
plant
aglaia
foveolata
known
inhibit
aspglualaasp
dead
box
rna
helicas
eukaryot
initi
requir
unwind
structur
untransl
region
thu
impair
rna
translat
exert
signific
inhibit
zikv
replic
cell
primari
human
hepatocyt
n
retinamid
fenretinid
activ
retinoid
receptor
inhibit
prolifer
cancer
cell
induc
apoptosi
inhibit
zikv
cell
cultur
significantli
reduc
serum
viremia
brain
viral
burden
mice
decreas
rate
viral
rna
synthesi
though
via
direct
inhibit
activ
viral
replicas
zikv
reli
polyamin
translat
transcript
drug
target
polyamin
biosynthet
pathway
difluoromethylornithin
dfmo
eflornithin
fdaapprov
drug
use
treat
trypanosomiasi
hirsut
cancer
well
diethylnorspermin
denspm
limit
viral
replic
cell
zikv
replic
particl
morphogenesi
take
place
associ
virusinduc
organellelik
structur
deriv
membran
endoplasm
reticulum
er
figur
de
novo
synthes
posit
strandrna
packag
form
envelop
immatur
virion
er
enter
secretori
pathway
transgolgi
network
prm
cleav
viru
releas
infect
cell
figur
ermembran
multiprotein
complex
oligosaccharyltransferas
ost
complex
report
critic
host
factor
flaviviru
multipl
regard
shown
nlink
glycosyl
chemic
modul
ost
complex
block
zikvrna
replic
differ
cell
type
similarli
host
erassoci
signal
peptidas
spase
essenti
membranebound
serin
proteas
complex
involv
cleavag
signal
peptid
newli
synthes
secretori
membran
protein
er
also
process
flaviviru
prm
e
structur
protein
also
report
cavinafungin
alaninalcontain
lipopeptid
fungal
origin
potent
inhibit
growth
zikvinfect
cell
nitazoxanid
broadspectrum
antivir
agent
approv
fda
antiprotozoan
potenti
activ
sever
virus
clinic
trial
rotaviru
noroviru
gastroenter
chronic
hepat
b
chronic
hepat
c
influenza
also
inhibit
viru
infect
target
postattach
step
like
viru
genom
replic
likewis
brefeldin
penicillium
sp
product
inhibit
protein
transport
er
golgi
apparatu
inhibit
zikv
multipl
emetin
antiprotozo
agent
inhibit
zikv
polymeras
activ
disrupt
lysosom
function
zikv
infect
lead
celldeath
induc
host
neuron
apoptosi
propag
therebi
bithionol
caspas
inhibitor
inhibit
zikv
strain
differ
geograph
origin
vero
cell
human
astrocyt
similarli
use
drug
repurpos
screen
molecul
found
emricasan
pancaspas
inhibitor
restrain
zikvinduc
increas
activ
current
phase
clinic
trial
chronic
hepat
c
viru
hcv
infect
patient
protect
human
cortic
neural
progenitor
cell
npc
monolay
threedimension
organoid
cultur
show
neuroprotect
activ
without
suppress
viral
replic
addit
bortezomib
dipeptid
boron
proteasom
inhibitor
approv
treatment
multipl
myeloma
mantl
cell
nonhodgkin
lymphoma
regul
famili
protein
also
describ
zikv
inhibitor
similarli
differ
cyclindepend
kinas
cdk
inhibitor
alpha
acetylamino
alphamethyln
benzeneacetamid
reduc
zikvinfect
propag
howev
cdk
inhibitor
suitabl
treatment
pregnant
women
could
use
treatment
nonpregn
patient
prevent
complic
associ
zikv
infect
need
specif
host
lipid
flaviviru
replic
particl
envelop
make
lipid
metabol
potenti
target
antivir
search
even
though
manipul
major
metabol
pathway
lipid
biosynthesi
envisag
danger
antivir
approach
due
undesir
effect
could
detriment
host
current
use
drug
ibuprofen
aspirin
inhibitor
statin
hmgcoa
reductas
inhibitor
highlight
feasibl
lipidbas
therapeut
accordingli
inhibit
key
enzym
involv
fatti
acid
synthesi
acetylcoa
carboxylas
acc
fatti
acid
synthas
fasn
potenti
target
antizikv
therapi
line
report
nordihydroguaiaret
acid
ndga
deriv
tetraomethyl
nordihydroguaiaret
terameprocol
two
compound
disturb
lipid
metabol
probabl
interf
sterol
regulatori
elementbind
protein
srebp
pathway
inhibit
infect
zikv
wnv
like
impair
viral
replic
structur
unrel
inhibitor
srebp
pathway
diethylamino
methyl
n
ethyl
n
dihydrochlorid
fatostatin
way
depend
cholesterol
differ
process
flaviviru
infect
also
provid
suitabl
target
antivir
strategi
mention
reduc
viremia
viral
load
vitro
also
reduc
mortal
prevent
microcephali
mice
decreas
viral
load
urin
serum
nonhuman
infect
primat
lovastatin
mevastatin
hypolipidem
agent
hmgcoa
inhibitor
belong
famili
statin
wide
use
lower
cholesterol
patient
hypercholesterolemia
previous
shown
present
antivir
activ
dengu
hepat
c
virus
agent
propos
therapeut
candid
zikv
fact
lovastatin
attenu
nervou
injuri
anim
model
gb
likewis
imipramin
fdaapprov
antidepress
inhibit
zikvrna
replic
virion
product
human
skin
fibroblast
probabl
interf
intracellular
cholesterol
transport
regard
sphingolipid
metabol
involv
flaviviru
infect
treatment
neutral
sphingomyelinas
inhibitor
reduc
zikv
product
affect
viral
morphogenesi
describ
flavivirus
final
sinc
adenosin
monophosphateactiv
protein
kinas
ampk
master
regul
lipid
metabol
activ
metformin
reduc
zikv
infect
impair
viral
replic
thu
target
lipid
metabol
could
provid
therapeut
altern
discoveri
hostdirect
antivir
zikv
protein
viral
rnadepend
rna
polymeras
respons
rna
synthesi
also
inhibit
interferon
ifn
signal
act
signal
transduc
activ
transcript
protein
thu
major
target
antivir
design
besid
proven
antivir
activ
differ
nucleosid
analog
inhibitor
sever
inhibitor
biosynthesi
nucleosid
purin
pyrimidin
also
impair
zikv
replic
figur
ribavirin
inhibitor
inosin
monophosph
dehydrogenas
impdh
antivir
activ
sever
rna
virus
mechan
action
entir
clear
may
act
guanosin
synthesi
inhibitor
viral
cap
synthesi
inhibitor
viral
rna
mutagen
induc
lethal
mutagenesi
use
cellbas
assay
antivir
activ
drug
initi
observ
later
report
although
activ
zikv
detect
vero
cell
drug
inhibit
viru
multipl
human
cell
line
includ
liver
rhabdomyosarcoma
rd
cell
studi
confirm
inhibitori
activ
ribavirin
zikv
strain
differ
geograph
origin
variou
type
cell
human
neural
progenitor
cell
hnpc
human
dermal
fibroblast
hdf
human
lung
adenocarcinoma
cell
even
vero
cell
still
drug
shown
abrog
viremia
zikvinfect
mice
lack
type
ifn
signal
highli
sensit
zikv
infect
exhibit
lethal
outcom
two
inhibitor
impdh
merimepodib
mmpd
mycophenol
acid
mpa
also
inhibit
zikvrna
replic
differ
cell
type
includ
cell
human
cervic
placent
cell
neural
stem
primari
amnion
cell
howev
author
describ
mpa
littl
effect
zikv
replic
show
signific
cell
toxic
likewis
azathioprin
anoth
inhibitor
purin
synthesi
immunosuppress
impair
zikv
replic
hela
cell
nonetheless
use
pregnant
women
recommend
describ
contradictori
result
stress
differ
drug
treatment
may
consequ
differ
viral
strain
cell
type
methodolog
use
assess
inhibitor
purin
biosynthesi
compound
inhibit
synthesi
pyrimidin
also
effect
zikv
replic
figur
viru
highli
suscept
brequinar
cid
treatment
cell
cultur
howev
note
report
brequinar
well
antivir
activ
may
due
pyrimidin
depriv
rather
induct
cellular
immun
respons
similarli
inhibitor
pyrimidin
synthesi
gemcitabin
activ
cellular
caspas
although
lower
effici
probabl
due
lower
solubl
finasterid
analog
testosteron
inhibit
type
ii
type
iii
test
benign
prostat
hyperplasia
male
pattern
bald
reduc
zikv
replic
sever
compound
shown
antizikv
activ
inhibit
viral
entri
andor
rna
synthesi
although
mechan
action
yet
fulli
elucid
among
antiparasit
ivermectin
use
mainli
worm
infect
pyrimethamin
folic
acid
antagonist
inhibit
dihydrofol
reductas
thu
dna
rna
synthesi
classifi
pregnanc
categori
c
initi
use
treat
malaria
toxoplasmosi
cystoisosporiasi
antibiot
azithromycin
prevent
infect
replic
virusmedi
cell
dead
kitasamycin
natur
product
streptomyc
narbonensi
inhibit
protein
biosynthesi
drug
use
prevent
chemotherapyinduc
nausea
vomit
palonosetron
fdaapprov
antagonist
antidepress
like
sertralin
select
serotonin
reuptak
inhibitor
cyclosporin
also
use
rheumatoid
arthriti
psoriasi
crohn
diseas
nephrot
syndrom
organ
transplant
believ
lower
activ
tcell
current
clinic
trial
ti
possibl
use
amelior
neuron
cellular
damag
similarli
chemic
screen
found
hippeastrin
hydrobromid
hh
activ
compon
tradit
chines
medicin
amodiaquin
dihydrochlorid
dihydr
aq
fdaapprov
drug
treatment
malaria
inhibit
zikv
infect
human
pluripot
stem
cellderiv
cortic
npc
adult
mous
brain
vivo
even
infect
alreadi
ongo
mechan
action
known
besid
drug
act
host
target
directli
implic
viral
cycl
compound
prevent
undesir
effect
zikv
infect
regard
zikv
infect
lead
massiv
neuron
damag
especi
neural
progenitor
cell
neurodegener
via
direct
replic
neuron
cell
possibl
increas
excitotox
via
activ
nmethyldaspart
receptor
nmdar
depend
neuron
excitotox
nearbi
cell
memantin
pregnanc
categori
b
fdaapprov
drug
wide
use
treat
patient
alzheim
diseas
well
nmdar
blocker
dizocilpin
agmatin
sulfat
ifenprodil
prevent
neuron
damag
death
intraocular
pressur
increas
induc
zikv
infect
infect
mice
affect
viru
replic
point
possibl
use
prevent
minim
zikvrel
microcephali
pregnanc
ebselen
eb
antioxid
reduc
oxid
stress
improv
histopatholog
featur
testicular
injuri
studi
model
current
clinic
trial
variou
diseas
show
minor
effect
reduc
zikv
progeni
product
viral
e
protein
express
overal
surviv
viremia
level
challeng
mice
howev
note
eb
reduc
zikvinduc
effect
testicular
oxid
stress
leucocyt
infiltr
product
proinflammatori
respons
wherea
model
maletofemal
mous
sperm
transfer
drug
improv
testicular
patholog
prevent
sexual
transmiss
zikv
ifn
play
key
role
elimin
pathogen
releas
upon
activ
innat
immun
respons
infect
virus
way
zikv
infect
induc
ifn
signal
pathway
activ
cytoplasm
retino
acid
induc
gene
protein
like
receptor
rlr
sever
type
iii
ifnstimul
gene
drive
subsequ
activ
janu
kinas
jak
stat
innat
immun
pathway
confer
resist
zikv
infect
differ
studi
show
inhibit
zikv
replic
cell
cultur
treatment
pregnant
mice
reduc
zikv
infect
addit
interferoninduc
transmembran
protein
impair
earli
stage
zikv
infect
even
prevent
zikvinduc
cell
death
likewis
report
interferonactiv
small
molecul
avc
strongli
inhibit
replic
zikv
cell
cultur
howev
also
known
viru
capabl
evad
type
ifn
respons
act
jakstat
signal
pathway
type
ifn
might
mediat
pregnanc
complic
includ
spontan
abort
growth
restrict
case
use
ifn
zikv
alon
combin
antivir
deserv
studi
screen
librari
known
human
microrna
mirna
small
noncod
rna
sncrna
modul
gene
express
posttranscript
regul
broad
rang
cellular
process
sever
mirna
found
inhibit
zikv
increas
capabl
infect
cell
respond
infect
interferonbas
innat
immun
pathway
anoth
altern
interven
epigenet
regul
use
epigenet
modul
instanc
histon
methyltransferas
suppress
gene
transcript
shown
inhibitor
n
methyl
reduc
zikv
multipl
cell
cultur
activ
cellular
antivir
immun
respons
case
studi
need
evalu
potenti
therapeut
capabl
immunomodul
zikv
infect
great
effort
late
made
find
compound
fight
zikv
infect
appli
differ
approach
repurpos
drug
known
antivir
activ
screen
bioactiv
molecul
differ
librari
well
natur
product
howev
alreadi
test
drug
found
inhibit
viral
replic
vitro
test
vivo
henc
sinc
mani
instanc
result
difficult
extrapol
human
would
hard
test
antivir
complet
entir
drug
develop
pipelin
addit
remark
mani
drug
could
untoward
effect
thu
care
evalu
conduct
use
clinic
practic
main
target
popul
antizikv
therapi
pregnant
women
patient
medic
complic
mani
alreadi
test
drug
direct
viral
structur
enzymat
protein
includ
instanc
anticanc
antiinflammatori
molecul
antibiot
antiparasit
howev
well
known
approach
easili
lead
appear
resist
sinc
flavivirus
requir
mani
host
factor
cooption
cellular
metabol
pathway
success
infect
host
cell
propag
effici
offer
opportun
search
host
target
therapeut
tool
mani
instanc
broad
spectrum
agent
effect
would
less
prone
emerg
mutant
escap
action
even
though
manipul
host
metabol
pathway
seen
danger
due
undesir
effect
could
detriment
host
success
diseas
make
realist
option
treatment
zikv
infect
